Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIEG: Irinotecan plus Epirubicin in Advanced Gastric Cancer
NCT01964027Phase 2Unknown
- Sponsor
- Anhui Medical University
- Start
- Oct 2013
- Primary completion
- Jul 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and epirubicin in gastric cancer (GC), sponsored by Anhui Medical University. Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabepirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01964027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964027.